pabi-dexamethason 20 mg tabletki
adamed pharma s.a. - dexamethasonum - tabletki - 20 mg
pabi-dexamethason 4 mg tabletki
adamed pharma s.a. - dexamethasonum - tabletki - 4 mg
nexpovio
stemline therapeutics b.v. - selinexor - szpiczak mnogi - Środki przeciwnowotworowe - nexpovio is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
furocef 250 mg tabletki powlekane
krka, d.d., novo mesto - cefuroximum - tabletki powlekane - 250 mg
furocef 500 mg tabletki powlekane
krka, d.d., novo mesto - cefuroximum - tabletki powlekane - 500 mg
etafry 1,5 mg/ml krople do oczu, roztwór
sifi s.p.a. - dexamethasoni natrii phosphas - krople do oczu, roztwór - 1,5 mg/ml
pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - szpiczak mnogi - Środki przeciwnowotworowe - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.